“estrogen is a hormone and a hormone by definition has multiple effects on the body … and the issue with estrogen is that there is a consistently small, but important, increased risk of blood clots in the legs and the lungs. we call it venous thromboembolism. that has to be weighed against the risk of benefit to that individual patient.”
hormone replacement therapy for menopause may pose risks if started later in life
women who are a decade past menopause — roughly 60 years or older — have a higher risk of blood clotting, so mht is not recommended for this cohort.
“there have been several studies and analyses that have come out in the last few years to inform and appropriately give health-care providers the information to have a conversation with their female patients,” abramson told ctv news.
abramson is one of the authors of the new guidelines and says they are designed to give doctors, nurses, pharmacists and other health professionals the tools to better understand the therapy protocols and risks. she also says each patient has individual risks and circumstances that factor into treatment.
“the women who are under 60 years of age who’ve had menopausal hormone therapy initiated shortly after their last menstrual period, there seems to be no increased risk for cardiovascular disease,” she told ctv. “and we have seen in general, there’s low risk for adverse events, including stroke, in the next few years,”
that being said, research indicates mht may decrease the risk of cardiovascular disease in certain circumstances. women who start menopause early may be at higher risk of heart disease, however, when these women underwent mht from their start of menopause until the average age of menopause, 51, risk of cardiovascular trouble appeared to decrease.
different approaches to menopause are available